{"entity":{"id":"sapu-nano","kind":"company","name":"Sapu Nano","aka":["SAPU NANO (US) LLC"],"tldr":"Sapu Nano reformulates existing cancer drugs as extremely small particles that can be given into a vein. Its first product, Sapu003, is an intravenous form of the mTOR inhibitor everolimus, in an early trial in several advanced solid tumours.","summary":"Sapu Nano is a San Diego nanomedicine company whose Deciparticle platform formulates water-insoluble drugs as nanoparticles smaller than 20 nm for intravenous use; its manufacturing is done at the Sapu Bioscience GMP facility in San Diego. The website links the platform's lineage to Vuong Trieu, co-inventor of Abraxane, and a survey paper on the platform was released by Oncotelic. Its lead product Sapu003 (SAPU-003) is a weekly intravenous Deciparticle formulation of everolimus; the company says it gives full systemic exposure to both mTOR complexes and reduces gut accumulation compared with oral everolimus. The first patient was dosed in May 2026. Its first registered cancer trial, NCT07369505, a phase 1b dose-escalation study of Sapu003 alone or with exemestane in advanced mTOR-sensitive solid tumours (HR-positive, HER2-negative breast cancer, renal cell carcinoma, neuroendocrine tumours, tuberous sclerosis complex-associated tumours and hepatocellular carcinoma) in Adelaide, Australia, was posted on ClinicalTrials.gov in January 2026.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://sapunano.com/"},{"label":"SAPU-003 programme page","url":"https://sapunano.com/sapu003/"},{"label":"Company news","url":"https://sapunano.com/news/"},{"label":"ClinicalTrials.gov: phase 1b trial of Sapu003 in mTOR-sensitive solid tumours (NCT07369505)","url":"https://clinicaltrials.gov/study/NCT07369505"}],"tags":[],"related":[],"cancers":["breast-hr-positive","rcc","neuroendocrine","hcc"],"sections":["targeted-therapy"],"technologies":["pi3k-akt-mtor-inhibitors"],"targets":["mtor"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year, ownership and financing are not stated on the company website. The relationship between Sapu Nano, Sapu Bioscience and Oncotelic is not set out on the pages read; the news page calls Sapu Nano a subsidiary without naming the parent.","The company's claims of 100% bioavailability and reduced toxicity are its own and come from preclinical and pharmacokinetic data; no clinical efficacy has been reported.","OnCo has no technology record for nanoparticle drug reformulation; the record is linked to PI3K, AKT and mTOR inhibitors because everolimus inhibits mTOR.","Company website read on 29 October 2026."],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://sapunano.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/sapu-nano/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"pi3k-akt-mtor-inhibitors","kind":"technology","name":"PI3K, AKT and mTOR inhibitors","route":"/technologies/pi3k-akt-mtor-inhibitors/"}],"target":[{"id":"mtor","kind":"target","name":"mTOR","route":"/targets/mtor/"}]}}